About Compugen’s GPCR Peptide Library
The more than 900 peptide molecules in Compugen’s GPCR peptide library were predicted through the use of Compugen’s GPCR Peptide Ligand Discovery Platform. The initial validation activities for this platform resulted in the predictive discovery of a number of novel peptides that were subsequently shown to have therapeutic potential in disease animal models of cardiovascular, fibrotic and inflammatory conditions. Further enhancements and extensions during, and subsequent to, the initial validation, have resulted in the current platform, which relies on a series of sequential computational biology models and machine learning capabilities for the prediction and selection of product candidates. The platform incorporates a proprietary model of the “peptidome,” an in silico prediction of putative human peptides, which includes thousands of novel predicted human peptide sequences, based on predicting cleavage sites in precursor proteins. The discovery platform utilizes proprietary machine-learning algorithms to analyze this peptidome and to identify peptides likely to activate GPCRs.
About DiscoveRx’s PathHunter Platform and GPCR related Technologies
DiscoveRx’s innovative approach to GPCR signaling assay development, using a simple, homogeneous, chemiluminescent, read-out based on β-galactosidase-based enzyme fragment complementation (EFC), is core to the success of many drug discovery programs. The emerging field of GPCR drug discovery is necessitating the analysis of GPCRs using multiple assay approaches. From the traditional second messenger signaling assays to the novel, universal β-arrestin recruitment assays for known and orphan GPCRs to the next generation platforms for studying GPCR internalisation and heterodimerisation, DiscoveRx is addressing current and emerging drug discovery needs through innovative GPCR assays and profiling services and by offering more than one signaling assay platform for a single GPCR target ( www.discoverx.com/gpcrs).About Compugen Compugen is a leading therapeutic product candidate discovery company, currently focused on biologics-based therapy to address important unmet needs in the fields of immunology and oncology, either for Compugen or its partners. Unlike traditional high throughput trial and error experimental based drug candidate discovery, Compugen’s discovery efforts are based on systematic and continuously improving in silico (by computer) product candidate prediction and selection followed by experimental validation, with selected product candidates being advanced in its Pipeline Program to the pre-IND stage. Compugen’s in silico predictive models utilize a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities. The Company’s business model primarily involves collaborations covering the further development and commercialization of Compugen-discovered product candidates and various forms of “discovery on demand” arrangements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2002, Compugen established an affiliate, Evogene Ltd. ( www.evogene.com) ( TASE: EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com. About DiscoveRx Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, CA and Birmingham, England. DiscoveRx is dedicated to the development and commercialization of cutting-edge solutions to study GPCRs, kinases and other major drug target classes, and many of their innovative products as well as service offerings have been widely adopted in global drug discovery campaigns. The Company core platforms 1) β-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and 2) KINOME scan in-vitro binding assay platform for kinase profiling are routinely deployed by leading pharmaceutical, biotech and academic laboratories on a worldwide basis. For more information on DiscoveRx products, please visit www.discoverx.com. This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading “Risk Factors” in Compugen's annual reports filed with the Securities and Exchange Commission.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts